Literature DB >> 9687380

Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells.

S Hayashi1, T Sugiyama, K Amano, H Isogai, E Isogai, M Aihara, M Kikuchi, M Asaka, K Yokota, K Oguma, N Fujii, Y Hirai.   

Abstract

Helicobacter pylori is a major etiological agent in gastroduodenal disorders. The adhesion of H. pylori to human gastric epithelial cells is the initial step of H. pylori infection. Inhibition of H. pylori adhesion is thus a therapeutic target in the prevention of H. pylori infection. Experiments were performed to evaluate the effect of rebamipide, a novel antiulcer agent, on H. pylori adhesion to gastric epithelial cells. MKN-28 and MKN-45 cells, derived from human gastric carcinomas, were used as target cells. Ten H. pylori strains isolated from patients with chronic gastritis and gastric ulcer were used in the study. We evaluated the effect of rebamipide on H. pylori adhesion to MKN-28 and MKN-45 cells quantitatively using our previously established enzyme-linked immunosorbent assay. The adhesion of H. pylori to MKN-28 and MKN-45 cells was significantly inhibited by pretreatment of these cells with 100 microg of rebamipide per ml. However, the adhesion was not affected by the pretreatment of H. pylori with rebamipide. On the other hand, the viabilities of H. pylori, MKN-28 cells, and MKN-45 cells were not affected by rebamipide. Our studies suggest that rebamipide inhibits the adhesion of H. pylori to gastric epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687380      PMCID: PMC105706     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease.

Authors:  D Y Graham
Journal:  J Gastroenterol Hepatol       Date:  1991 Mar-Apr       Impact factor: 4.029

2.  The glycerolipid receptor for Helicobacter pylori (and exoenzyme S) is phosphatidylethanolamine.

Authors:  C A Lingwood; M Huesca; A Kuksis
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Indicator medium for isolation of Campylobacter pylori.

Authors:  D M Queiroz; E N Mendes; G A Rocha
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

4.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

Review 5.  Chronic gastritis--a pathogenetic approach.

Authors:  J I Wyatt; M F Dixon
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

6.  Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propi oni c acid and related compounds.

Authors:  M Uchida; F Tabusa; M Komatsu; S Morita; T Kanbe; K Nakagawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-09       Impact factor: 1.645

7.  An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group.

Authors: 
Journal:  Lancet       Date:  1993-05-29       Impact factor: 79.321

8.  N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen.

Authors:  D G Evans; D J Evans; J J Moulds; D Y Graham
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

9.  Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori.

Authors:  D G Evans; T K Karjalainen; D J Evans; D Y Graham; C H Lee
Journal:  J Bacteriol       Date:  1993-02       Impact factor: 3.490

10.  Receptor affinity purification of a lipid-binding adhesin from Helicobacter pylori.

Authors:  C A Lingwood; G Wasfy; H Han; M Huesca
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

View more
  8 in total

Review 1.  15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.

Authors:  Tetsuo Arakawa; Kazuhide Higuchi; Yasuhiro Fujiwara; Toshio Watanabe; Kazunari Tominaga; Eiji Sasaki; Nobuhide Oshitani; Toshikazu Yoshikawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide.

Authors:  T Matysiak-Budnik; A Thomas-Collignon; F Mégraud; M Heyman
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.

Authors:  Hajime Isomoto; Hisashi Furusu; Ken Ohnita; Chun-Yang Wen; Kenichiro Inoue; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

4.  A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori.

Authors:  Y Yamaoka; D H Kwon; D Y Graham
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

5.  Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.

Authors:  Masaki Takayama; Shigenaga Matsui; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

6.  Suppressive Effects of Selected Food Phytochemicals on CD74 Expression in NCI-N87 Gastric Carcinoma Cells.

Authors:  Hirotaka Sekiguchi; Kazuto Washida; Akira Murakami
Journal:  J Clin Biochem Nutr       Date:  2008-09       Impact factor: 3.114

7.  Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome.

Authors:  Mohan H Kudur; Manjunath Hulmani
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

8.  Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies.

Authors:  Dmitrii N Andreev; Igor V Maev; Diana T Dicheva
Journal:  J Clin Med       Date:  2019-09-19       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.